News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:56 2026-06-05 EDT			5-day change	1st Jan Change
120.79 ^USD	+0.44%		+1.74%	+14.75%

06-04	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases	MT
06-04	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports	MT

All News

Mentions Relevance

06-04	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases	MT
06-04	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports	MT
06-04	Merck & Co., Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 10:30 AM
06-02	Agilent Gets US FDA Clearance for Expanded Use of Cancer Test on Dako Omnis Platform	MT
06-02	Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
06-01	Merck & Co., Inc. - Special Call
06-01	Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting	AQ
05-29	Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation	CI
05-29	Merck Gets FDA Breakthrough Designation for Calderasib in NSCLC	DJ
05-29	Merck's Investigational Non-Small Cell Lung Cancer Therapy Granted US FDA Breakthrough Therapy Designation	MT
05-29	FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)	BU
05-28	Declaration of Voting Results by Merck & Co., Inc.	CI
05-28	Declaration of Voting Results by Merck & Co., Inc.	CI
05-28	Declaration of Voting Results by Merck & Co., Inc.	CI
05-28	Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care	AQ
05-28	Merck to Participate in the Jefferies Global Healthcare Conference	BU
05-27	Merck chicken bronchitis vaccine approved for use in China	RE
05-26	Merck Co Inc declares Q3 2026 dividend of $0.85 per share	RE
05-26	Merck Keeps Quarterly Dividend at $0.85 a Share, Payable July 8 to Holders of Record June 15	MT
05-26	Merck Announces Third-Quarter 2026 Dividend	BU
05-26	Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2026, Payable on July 8, 2026	CI
05-26	Adcendo ApS and MSD Enter Clinical Collaboration and Supply Agreement to Evaluate ADCE-T02 in Combination with KEYTRUDA (Pembrolizumab) in Phase Ib Study in Patients with Advanced Solid Tumors	CI
05-22	Merck's Keytruda, Padcev Combination to Treat Bladder Cancer Receives Positive EU Recommendation; Shares Up Pre-Bell	MT
05-22	Merck Secures EU Backing for Keytruda-Padcev in Bladder Cancer Patients Subset	DJ
05-22	Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer	BU